<HTML lang="en" dir="ltr" class="client-nojs">
<style type="text/css">
A:before { content:' '; } 
A:after { content:' '; } 
SPAN:before { content:' '; } 
SPAN:after { content:' '; } 
</style>
<BODY class="mediawiki ltr sitedir-ltr ns-0 ns-subject page-Team_Aalto-Helsinki_Model_Theory skin-igem action-view"><DIV id="globalWrapper"><DIV id="content" class="mw-body" role="main"><DIV id="top_title"><H1 id="firstHeading" class="firstHeading"><SPAN dir="auto">Team:Aalto-Helsinki/Model Theory</SPAN></H1></DIV><DIV id="HQ_page"><DIV id="bodyContent"><DIV id="mw-content-text" lang="en" dir="ltr" class="mw-content-ltr"><P><TITLE>Aalto-Helsinki</TITLE></P><DIV id="dropdown"><UL><LI class="active has-sub"><A class="lab" href="https://2017.igem.org/Team:Aalto-Helsinki/Description">Laboratory</A></LI><LI><A href="https://2017.igem.org/Team:Aalto-Helsinki/Description">Overview</A></LI><LI><A href="https://2017.igem.org/Team:Aalto-Helsinki/Laboratory_Theory">Theoretical Background</A></LI><LI class="has-sub"><A href="https://2017.igem.org/Team:Aalto-Helsinki/Experiments">Materials and Methods</A></LI><LI class="last"><A href="https://2017.igem.org/Team:Aalto-Helsinki/Protocols">Protocols</A></LI></UL><LI><A href="https://2017.igem.org/Team:Aalto-Helsinki/Results">Results and Discussion</A></LI><LI><A href="https://2017.igem.org/Team:Aalto-Helsinki/Laboratory_Future">Future Perspectives</A></LI><LI class="active has-sub"><A class="mod" href="https://2017.igem.org/Team:Aalto-Helsinki/Model">Modeling</A></LI><LI><A href="https://2017.igem.org/Team:Aalto-Helsinki/Model">Overview</A></LI><LI><A href="https://2017.igem.org/Team:Aalto-Helsinki/Model_Theory">Theoretical Background</A></LI><LI><A href="https://2017.igem.org/Team:Aalto-Helsinki/Model_Setup">Simulation Setup</A></LI><LI><A href="https://2017.igem.org/Team:Aalto-Helsinki/Model_Results">Results and Discussion</A></LI><LI class="active has-sub"><A class="hp" href="https://2017.igem.org/Team:Aalto-Helsinki/Human_Practices">Human Practices</A></LI><LI><A href="https://2017.igem.org/Team:Aalto-Helsinki/Human_Practices">Overview</A></LI><LI><A href="https://2017.igem.org/Team:Aalto-Helsinki/Story">Project</A></LI><LI><A href="https://2017.igem.org/Team:Aalto-Helsinki/Engagement">Public Outreach</A></LI><LI><A href="https://2017.igem.org/Team:Aalto-Helsinki/HP/Silver">Judging</A></LI><LI class="active has-sub"><A class="com" href="https://2017.igem.org/Team:Aalto-Helsinki/Community">Community</A></LI><LI><A href="https://2017.igem.org/Team:Aalto-Helsinki/Community">Overview</A></LI><LI><A href="https://2017.igem.org/Team:Aalto-Helsinki/Parts">Parts</A></LI><LI><A href="https://2017.igem.org/Team:Aalto-Helsinki/Composite_Part">Composite Part</A></LI><LI><A href="https://2017.igem.org/Team:Aalto-Helsinki/Improve">Improved Part</A></LI><LI><A href="https://2017.igem.org/Team:Aalto-Helsinki/InterLab">InterLab</A></LI><LI><A href="https://2017.igem.org/Team:Aalto-Helsinki/Collaborations">Collaborations</A></LI><LI class="active has-sub"><A class="peo" href="https://2017.igem.org/Team:Aalto-Helsinki/Team">People</A></LI><LI><A href="https://2017.igem.org/Team:Aalto-Helsinki/Team">Team Members</A></LI><LI><A href="https://2017.igem.org/Team:Aalto-Helsinki/Advisors">Advisors</A></LI><LI><A href="https://2017.igem.org/Team:Aalto-Helsinki/Attributions">Attributions</A></LI><LI><A href="https://2017.igem.org/Team:Aalto-Helsinki/Sponsors">Sponsors</A></LI></DIV><DIV id="color-block-mod"><SPAN><DIV class="text1">MODELING</DIV><DIV class="text2"><A href="https://2017.igem.org/Team:Aalto-Helsinki/Model">Modeling Overview</A><A style="text-decoration: underline" href="https://2017.igem.org/Team:Aalto-Helsinki/Model_Theory">Theoretical Background</A><A href="https://2017.igem.org/Team:Aalto-Helsinki/Model_Setup">Simulation Setup</A><A href="https://2017.igem.org/Team:Aalto-Helsinki/Model_Results">Results and Discussion</A></DIV></SPAN></DIV><DIV class="container"><DIV class="introtext"><H3 style="color: #CC9933">Theoretical Background</H3><P id="paragraph">
Owing to the global rise in the number of multi-resistant bacteria species, development of highly efficient
antimicrobial agents less prone to induce resistance in microbes has garnered growing interest. Antimicrobial peptides (AMPs), also sometimes referred to as host-defense peptides, often showcase broad and effective antimicrobial activity, acting as a part of the innate immune system. Dermcidin is one of the major
antimicrobial peptides detected on human skin [<A name="ref6" href="#refl6">6</A>, <A name="ref11" href="#refl11">11</A>]. Dermcidin and its derivatives have been shown to
exhibit broad scale antimicrobial activity against a number of pathogens, including <I>M. tuberculosis</I><A name="ref10" href="#refl10">[10]</A>
and <I>S. aureus</I><A name="ref14" href="#refl14">[14]</A>.
</P><P id="paragraph">
DCD-1L is a 48 amino acid peptide originating from the proteolytically processed 110 amino acid
precursor peptide. DCD-1L has been shown to exhibit broad scale antimicrobial activity against a range
of pathogens, including <I>E. coli</I>, <I>E. faecalis</I> and <I>S. aureus</I>. <A name="ref11" href="#refl11">[11]</A> Like other dermcidin derivatives, the peptide
has an overall negative net charge at physiological pH, contrary to the commonly expected positive charge
of AMPs [<A name="ref8" href="#refl8">8</A>, <A name="ref10" href="#refl10">10</A>]. There has been controversial debate regarding the exact mechanism of action of dermcidin
and its derivative peptides, including DCD-1L [<A name="ref15" href="#refl15">15</A>, <A name="ref4" href="#refl4">4</A>, <A name="ref14" href="#refl14">14</A>, <A name="ref10" href="#refl10">10</A>]. However, generally the presence of α-helical
structures has been attributed as a marker for antimicrobial activity, as is common for a wide variety of
AMPs <A name="ref2" href="#refl2">[2]</A>.
</P></DIV></DIV><DIV id="quote-block-mod"><DIV style="font-size: 25px !important;" class="quote-text">Despite the apparent lack of conformational studies of dermcidin derivatives in low salt aqueous environments, the antimicrobial activity of dermcidin has been widely mapped in such conditions</DIV></DIV><DIV class="container"><DIV class="basictext"><P id="paragraph">
The experimental data regarding the three dimensional structure of dermcidin has thus far been
mostly limited to circular dichroism (CD) spectroscopy studies, most often carried out in solvents that
promote stabilization of protein secondary structure, such as TFE, as well as other membrane mimicking
environments. [<A name="ref11" href="#refl11">11</A>, <A name="ref10" href="#refl10">10</A>, <A name="ref7" href="#refl7">7</A>] However, dermcidin appears as active in its native environment of sweat, which is a
naturally acidic, mostly aqueous environment with a pH of 4.0 - 6.8 and also contains low concentrations
of monovalent and divalent ions, including sodium (20 - 60 mM), chloride (20 - 80 mM), potassium (10
mM) and magnesium (1 mM). The few conformational studies of dermcidin in environments effectively
mimicking its natural habitat, commonly report a random coil secondary structure with no α-helicity [<A name="ref14" href="#refl14">14</A>, <A name="ref10" href="#refl10">10</A>]. Despite the apparent lack of conformational studies of dermcidin derivatives in low salt aqueous
environments, the antimicrobial activity of dermcidin has been widely mapped in such conditions [<A name="ref11" href="#refl11">11</A>, <A name="ref14" href="#refl14">14</A>, <A name="ref10" href="#refl10">10</A>, <A name="ref4" href="#refl4">4</A>]. According to prior studies, the antimicrobial activity of dermcidin appears independent of pH level
and salt concentration <A name="ref11" href="#refl11">[11]</A>. Additionally, studies have underlined the importance of AMP interaction with
monovalent and divalent ions, such as those found in human sweat, in regards to induced antimicrobial
activity [<A name="ref15" href="#refl15">15</A>, <A name="ref3" href="#refl3">3</A>, <A name="ref5" href="#refl5">5</A>].
</P><P id="paragraph">
Molecular modeling and computer simulation help us understand the properties of assemblies of
molecules in terms of structure and atomic scale interactions between the different components of the
system. Computational chemistry methods serve as a complement to conventional experiments and often
enable examination of properties that cannot be accurately or directly examined though a traditional
experimental setup. Simulation also enables examination of conditions that may be unachievable in
standard laboratory conditions, such as extreme temperatures or pressure. Computer simulations enable
examination of phenomena in nanoscopic length and time scales and enable exact calculation of bulk
properties based on initial assumptions about the interactions between the molecules. Additionally,
computer simulation provides a bridge between theory and experiment: a theory can be tested by
conducting a variety of simulations using a common model, and the validity of the model can be evaluated through
comparison to experimental data. The two main families of computer simulation techniques are molecular
dynamics (MD) and Monte Carlo (MC) methods. Additionally, many hybrid approach methods that combine
aspects of both MD and MC approaches exist. [<A name="ref12" href="#refl12">12</A>, <A name="ref13" href="#refl13">13</A>, <A name="ref16" href="#refl16">16</A>]
</P><P id="paragraph">
Although all molecular systems can be theoretically described accurately through quantum mechanics,
<I>ab initio</I> based methods remain inaccessible for description of complex, large system due to their high
computational expense. Alternatively, a molecular system can be described using classical mechanics
as parametrized by a force field. A force field is a collection of energy functions and their associated
parameters for describing the intra-molecular and inter-molecular interactions in a molecular system.
Prior computational studies of dermcidin have concentrated on exploring the mechanism of action of
the peptide, with emphasis on peptide behavior in environments mimicking the bacterial cell membrane,
which the peptide is assumed to interact with [<A name="ref15" href="#refl15">15</A>, <A name="ref7" href="#refl7">7</A>, <A name="ref1" href="#refl1">1</A>]. Both experimentally and computationally,
dermcidin has been found to assume a helical conformation in membrane conditions [<A name="ref10" href="#refl10">10</A>, <A name="ref15" href="#refl15">15</A>, <A name="ref7" href="#refl7">7</A>]. On the
molecular dynamics front, special interest has been directed towards the behavior of a dermcidin tetramer
in a bacteria mimicking phospholipid membrane [<A name="ref15" href="#refl15">15</A>, <A name="ref7" href="#refl7">7</A>].
</P><P id="paragraph">
Here, we simulate a DCD-1L peptide surrounded by water, both in the presence of counter ions
(due to the peptide's intrinsic net charge) and with added salt, using molecular dynamics simulations.
The simulations were carried out using the GROMOS force field parameter set 53A6 <A name="ref9" href="#refl9">[9]</A>. Based on the
computed molecular dynamics trajectories, we probe the evolution of secondary structure of DCD-1L and
its other physical properties in different salt concentration and temperature environments. This examination
of DCD-1L stability and activity in low salt aqueous environments provides crucial information for further
development of our hydrogel based product, a major component of which is an additive containing water
phase into which the dermcidin fusion peptide is incorporated.
</P><VIDEO style="width: 50%;" poster="https://static.igem.org/mediawiki/2017/3/32/T--Aalto-Helsinki--modeling-preview.png" controls=""><SOURCE src="https://static.igem.org/mediawiki/2017/2/2a/T--Aalto-Helsinki--modeling-video.mp4" type="video/mp4"><P style="font-style:italic;color:red;border-style:solid;border-width:2px;border-color:red">Your browser does not support HTML5 or support the media format. We recommend that you try a different browser or update your current browser.</P></SOURCE><P style="text-align: left" id="paragraph"><I>Figure 1. Movie render of the first few nano seconds of one of our simulation trajectories. Molecular dynamics allows us to observe evolution of molecular properties over time, such as peptide secondary structure, shape and hydrogen bonding.
 </I></P></VIDEO></DIV></DIV><DIV class="container"><H3>References</H3><P id="paragraph"><A name="refl1" href="#ref1">[1]</A> Becucci, L., Valensin, D., Innocenti, M., &amp; Guidelli, R. (2014, Jan). Dermcidin, an anionic antimicrobial
        peptide: influence of lipid charge, pH and Zn2+ on its interaction with a biomimetic membrane.
        <I>Soft Matter, 10</I>(4), 616–626.
        <A name="refl2" href="#ref2">[2]</A> Brogden, K. A. (2005, Mar). Antimicrobial peptides: pore formers or metabolic inhibitors in bacteria?
        <I>Nat. Rev. Microbiol., 3</I>(3), 238–250.
        <A name="refl3" href="#ref3">[3]</A> Brogden, K. A., De Lucca, A. J., Bland, J., &amp; Elliott, S. (1996, Jan). Isolation of an ovine pulmonary
        surfactant-associated anionic peptide bactericidal for Pasteurella haemolytica. <I>Proc. Natl. Acad.
        Sci. U.S.A., 93</I>(1), 412–416.
        <A name="refl4" href="#ref4">[4]</A> Burian, M., &amp; Schittek, B. (2015, Feb). The secrets of dermcidin action. <I>Int. J. Med. Microbiol., 305</I>(2),
        283–286
        <A name="refl5" href="#ref5">[5]</A> Eissa, A., Amodeo, V., Smith, C. R., &amp; Diamandis, E. P. (2011, Jan). Kallikrein-related peptidase-8
        (KLK8) is an active serine protease in human epidermis and sweat and is involved in a skin barrier
        proteolytic cascade. <I>J. Biol. Chem., 286</I>(1), 687–706.
        <A name="refl6" href="#ref6">[6]</A> Flad, T., Bogumil, R., Tolson, J., Schittek, B., Garbe, C., Deeg, M., . . . Kalbacher, H. (2002, Dec).
        Detection of dermcidin-derived peptides in sweat by ProteinChip technology. <I>J. Immunol. Methods,
        270</I>(1), 53–62.
        <A name="refl7" href="#ref7">[7]</A> Jung, H. H., Yang, S. T., Sim, J. Y., Lee, S., Lee, J. Y., Kim, H. H., . . . Kim, J. I. (2010, May).
        Analysis of the solution structure of the human antibiotic peptide dermcidin and its interaction
        with phospholipid vesicles. <I>BMB Rep, 43</I>(5), 362–368.
        <A name="refl8" href="#ref8">[8]</A> Nguyen, L. T., Haney, E. F., &amp; Vogel, H. J. (2011, Sep). The expanding scope of antimicrobial peptide
        structures and their modes of action. <I>Trends Biotechnol., 29</I>(9), 464–472.
        <A name="refl9" href="#ref9">[9]</A> Oostenbrink, C., Villa, A., Mark, A. E., &amp; van Gunsteren, W. F. (2004, Oct). A biomolecular force field
        based on the free enthalpy of hydration and solvation: the GROMOS force-field parameter sets
        53A5 and 53A6. <I>J Comput Chem, 25</I>(13), 1656–1676.
        <A name="refl10" href="#ref10">[10]</A> Paulmann, M., Arnold, T., Linke, D., Ozdirekcan, S., Kopp, A., Gutsmann, T., . . . Schittek, B. (2012,
        Mar). Structure-activity analysis of the dermcidin-derived peptide DCD-1L, an anionic antimicrobial
        peptide present in human sweat. <I>J. Biol. Chem., 287</I>(11), 8434–8443.
        <A name="refl11" href="#ref11">[11]</A> Schittek, B., Hipfel, R., Sauer, B., Bauer, J., Kalbacher, H., Stevanovic, S., . . . Garbe, C. (2001, Dec).
        Dermcidin: a novel human antibiotic peptide secreted by sweat glands. <I>Nat. Immunol., 2</I>(12),
        1133–1137.
        <A name="refl12" href="#ref12">[12]</A> Schlick, T. (2010). <I>Molecular modeling and simulation: an interdisciplinary guide: an interdisciplinary guide</I> (Vol. 21). Springer Science &amp; Business Media.
        <A name="refl13" href="#ref13">[13]</A> Schlick, T., Collepardo-Guevara, R., Halvorsen, L. A., Jung, S., &amp; Xiao, X. (2011, May). Biomolecularmodeling
        and simulation: a field coming of age. <I>Q. Rev. Biophys., 44</I>(2), 191–228.
        <A name="refl14" href="#ref14">[14]</A> Senyurek, I., Paulmann, M., Sinnberg, T., Kalbacher, H., Deeg, M., Gutsmann, T., . . . Schittek, B.
        (2009, Jun). Dermcidin-derived peptides show a different mode of action than the cathelicidin
        LL-37 against Staphylococcus aureus. <I>Antimicrob. Agents Chemother., 53</I>(6), 2499–2509.
        <A name="refl15" href="#ref15">[15]</A> Song, C., Weichbrodt, C., Salnikov, E. S., Dynowski, M., Forsberg, B. O., Bechinger, B., . . . Zeth, K.
        (2013, Mar). Crystal structure and functional mechanism of a human antimicrobial membrane
        channel. <I>Proc. Natl. Acad. Sci. U.S.A., 110</I>(12), 4586–4591.
        <A name="refl16" href="#ref16">[16]</A> van Gunsteren, W. F., Bakowies, D., Baron, R., Chandrasekhar, I., Christen, M., Daura, X., . . . Yu,
        H. B. (2006, Jun). Biomolecular modeling: Goals, problems, perspectives. <I>Angew. Chem. Int. Ed.
        Engl., 45</I>(25), 4064–4092.
</P></DIV><FOOTER><DIV class="footer-social"><DIV class="texts"><UL class="pe-social"><A href="https://2017.igem.org/Team:Aalto-Helsinki">HOME</A><A href="http://www.aalto.fi/en/">AALTO UNIVERSITY</A><A href="https://www.helsinki.fi/en">UNIVERSITY OF HELSINKI</A><A href="https://2017.igem.org/Team:Aalto-Helsinki/Map">SITE MAP</A></UL></DIV></DIV></FOOTER></DIV></DIV></DIV></DIV></DIV></BODY></HTML>